Calgb/Swog 80405: Phase III Trial of Irinotecan/5-Fu/Leucovorin (Folfiri) or Oxaliplatin/5-Fu/Leucovorin (Mfolfox6) with Bevacizumab (Bv) or Cetuximab (Cet) for Patients (Pts) with Expanded Ras Analyses Untreated Metastatic Adenocarcinoma of the Colon Or Rectum (Mcrc)

Publication | Closed Access

DOI

110

Citations

References

2014

Year

Heinz‐Josef Lenz, Donna Niedzwiecki, Federico Innocenti, Charles D. Blanke, M.R. Mahony, Bert H. O’Neil, James E. Shaw, Blasé N. Polite, Howard S. Höchster, J. Atkins,

Annals of Oncology

Calgb/swog 80405Colon Or RectumGastrointestinal OncologyMedicinePhase Iii TrialColorectal CancerPathologyCancer TreatmentOncologyRadiation OncologyMolecular Oncology